GMP Cell Banking Services Market, By Cell Type (Mammalian, Microbial, Insect, Yeast, Avian, Stem Cell Type, Others), By End User (Biopharmaceutical Companies, Contract Manufacturing Organizations), and By Region (North America, Latin America, Europe, Asia

GMP Cell Banking Services Market, By Cell Type (Mammalian, Microbial, Insect, Yeast, Avian, Stem Cell Type, Others), By End User (Biopharmaceutical Companies, Contract Manufacturing Organizations), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

GMP cell banking services is termed as the storing of cells of specific genome for the purpose of future use in a product or medicinal needs. Different types of cell lines stored in cell banks constitute of mammalian cells, microbial cells, insect cell lines, yeast cells, avian cells, and stem cells. Increasing funding for R&D in rare diseases is expected to boost growth of the global GMP cell banking services market over the forecast period. Furthermore, rapidly increasing biotechnology sector in developing countries along with increased government initiatives to promote biotechnology industry is also expected to propel the growth of the market during the forecast period.

Key features of the study:

This report provides in-depth analysis of the GMP Cell Banking Services market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global GMP Cell Banking Services market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, WuXi AppTec Group, Charles River Laboratories International, Inc., Eurofins Scientific, Merck KGaA, Lonza Group Ltd., SGS Ltd., ViruSure GmbH, Austrianova, Goodwin Biotechnology Inc., and Paragon Bioservices, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global GMP Cell Banking Services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GMP Cell Banking Services market

Detailed Segmentation:

GMP Cell Banking Services Market, By Cell Type:
Mammalian
Microbial
Insect
Yeast
Avian
Stem Cell Type
Others
GMP Cell Banking Services Market, By End User:
Biopharmaceutical Companies
Contract Manufacturing Organizations
GMP Cell Banking Services Market, By Region:
North America
By Cell Type
Mammalian
Microbial
Insect
Yeast
Avian
Stem Cell Type
Others
By End User
Biopharmaceutical Companies
Contract Manufacturing Organizations
By Country:
U.S.
Canada
Latin America
By Cell Type
Mammalian
Microbial
Insect
Yeast
Avian
Stem Cell Type
Others
By End User
Biopharmaceutical Companies
Contract Manufacturing Organizations
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Cell Type
Mammalian
Microbial
Insect
Yeast
Avian
Stem Cell Type
Others
By End User
Biopharmaceutical Companies
Contract Manufacturing Organizations
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Cell Type
Mammalian
Microbial
Insect
Yeast
Avian
Stem Cell Type
Others
By End User
Biopharmaceutical Companies
Contract Manufacturing Organizations
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Cell Type
Mammalian
Microbial
Insect
Yeast
Avian
Stem Cell Type
Others
By End User
Biopharmaceutical Companies
Contract Manufacturing Organizations
By Country:
GCC
Israel
Rest of Middle East
Africa
By Cell Type
Mammalian
Microbial
Insect
Yeast
Avian
Stem Cell Type
Others
By End User
Biopharmaceutical Companies
Contract Manufacturing Organizations
By Country:
South Africa
Central Africa
North Africa
Company Profiles
WuXi AppTec Group *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Charles River Laboratories International, Inc.
Eurofins Scientific
Merck KGaA
Lonza Group Ltd.
SGS Ltd.
ViruSure GmbH
Austrianova
Goodwin Biotechnology Inc.
Paragon Bioservices, Inc.
“*” marked represents similar segmentation in other categories in the respective section.